Biomarkers driven treatment of selected NSCLC: ALK EML4; Crizotinib; Crizotinib resistance; 2nd generation drugs

Date 16 December 2015
Event ESMO Preceptorship on NSCLC, Singapore
Session Session 5 - Biomarker driven treatment
Topics Lung and other Thoracic Tumours
Anti-Cancer Agents & Biologic Therapy
Drug Development
Presenter T. Mitsudomi, JP